经导管主动脉瓣置换术后的非主动脉瓣心脏手术
基于STS成人心脏手术数据库2011至2019年数据,共识别666例TAVR术后非主动脉瓣心脏手术,涉及459名术者、308个中心。全队列30天死亡率为17.0%,可获取STS预测风险者的观察/预期死亡比为1.7。
要点
- TAVR术后非主动脉瓣手术量从2011年4例增至2019年204例,以冠状动脉旁路移植术和瓣膜手术为主。
- 全队列30天死亡率为17.0%,非计划TAVR取出者死亡率为40.4%(19/47)。
- 可获取STS预测风险的390例中观察/预期死亡比为1.7。
核心结论
- TAVR术后非主动脉瓣手术与高死亡率和观察/预期死亡比相关,TAVR团队在选择候选人时应关注「终身管理」策略,包括评估合并疾病。
研究设计与样本
- 基于STS成人心脏手术数据库的查询分析,纳入2011至2019年TAVR术后非主动脉瓣心脏手术共666例,包括47例(7.1%)非计划TAVR取出和3例(0.5%)中止操作。
- 666例手术由459名术者完成(中位每名术者1.0例),来自308个中心(中位每中心1.0例),占STS数据库参与中心的29%。
主要发现
- 手术量从2011年4例增至2019年204例,主要归因于冠状动脉旁路移植术(n=283;42.5%)和二尖瓣手术(n=258;38.7%)。
- 患者中位年龄75.0岁,51.4%有既往心脏手术史。
- 全队列30天死亡率为17.0%;机器人辅助二尖瓣手术组为41.7%(5/12),非计划TAVR取出组为40.4%(19/47),开胸心房途径经导管二尖瓣置换组为30.3%(10/33),主动脉修复组为29.8%(24/79)。
- 390例可获取STS预测风险者中,单纯冠状动脉旁路移植术组30天死亡率为8.4%(19/225),单纯二尖瓣修复或置换组为13.5%(21/155),全组为10.8%(42/390),对应观察/预期死亡比分别为1.8、1.8和1.7。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the rapid adoption of transcatheter aortic valve replacement (TAVR), the frequency and outcomes of nonaortic valve cardiac surgery after TAVR are unknown. METHODS: Nonaortic valve surgery after TAVR from 2011 to 2019 was queried using the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database. A total of 666 patients, including 47 (7.1%) unplanned TAVR explants and 3 (0.5%) aborted procedures during nonaortic valve procedures, were identified. RESULTS: These 666 procedures were performed by 459 surgeons (median, 1.0 case per surgeon) from 308 centers (median, 1.0 case per center), representing 29% of STS Database participants. The case number increased over time from 4 in 2011 to 204 in 2019, largely attributable to coronary artery bypass grafting (CABG) (n = 283; 42.5%) and mitral valve (n = 258; 38.7%) procedures. The median age patients of was 75.0 years, and 51.4% had undergone previous cardiac surgical procedures. The 30-day mortality of the entire cohort was 17.0%. Subgroups with particularly high mortality included patients with robot-assisted mitral surgery (n = 5/12; 41.7%), an unplanned TAVR explant (n = 19/47; 40.4%), open atrial transcatheter mitral valve replacement (n = 10/33; 30.3%), and aortic repair (n = 24/79; 29.8%). Among 390 patients with available STS predicted risk of mortality, the 30-day mortality in patients with isolated CABG, patients with isolated mitral repair or replacement, and in the entire group was 8.4% (n = 19/225), 13.5% (n = 21/155), and 10.8% (n = 42/390) with corresponding observed-to-expected mortality (O/E) ratios of 1.8, 1.8, and 1.7, respectively. CONCLUSIONS: Nonaortic valve operation after TAVR was associated with a high mortality and O/E ratio. The TAVR team must be mindful of a "lifetime management" strategy, including assessment of concurrent diseases during TAVR candidate selection.
引用
- Fukuhara S, Ailawadi G, Deeb GM, et al. Nonaortic Valve Cardiac Surgery After Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2021. PMID: 34843697. doi:10.1016/j.athoracsur.2021.09.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。